Antihypertensives and Nitrates Study
Objective: To evaluate potential pharmacodynamic interactions between Uprima® and commonly used cardiovascular medications
Study design: Multi-center, double-blind, randomized placebo-controlled, fixed-dose, crossover
Dose: Uprima® 5 mg, chronic therapeutic doses of antihypertensives and/or nitrates
Number of patients: 162 with hypertension and/or coronary disease
Measurements: Supine and standing blood pressure (BP) by Dinamap®, Holter monitor recordings and adverse events (AE)